Home › Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
 

Keywords :   


Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

2015-06-03 06:41:56| drugdiscoveryonline Home Page

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an investigational RNAi therapeutic, for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)

Tags: united states united states food

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Young face paying mortgage into retirement years
13.05Universal Credit claimants must seek 18 hours work
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
More »